Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
FlowCardia is a medical device company marketing catheters that reopen obstructed arteries in the legs, which can avoid amputation. Its lead product, the CROSSER™, uses high-frequency vibration to penetrate hard arterial blockages.
After Gilde led a large institutional financing round of growth capital, the company built a marketing and sales organization, expanded its product portfolio and developed into a high-growth, revenue-generating business. FlowCardia was acquired by C. R. Bard, Inc. (NYSE: BCR) in 2010. It was located in Sunnyvale, California.
More Flowcardia news
FlowCardia, Inc. Initiates CENTRAL Study Enrollment
FlowCardia, Inc. expands treatment options for patients with chronic total occlusion
FlowCardia, Inc. Launches FlowMate™ Injector to Optimize Performance
FlowCardia, Inc. Appoints Deborah DeFilippo CFO
Venture&Growth
Affimed
Affimed (Nasdaq: AFMD) is a German therapeutics company committed to utilizing the untapped potential of the innate immune system to restore patients’ natural ability to fight cancer. Affimed is developing a product pipeline consisting of three clinical-stage drug candidates, providing

Venture&Growth
AM-Pharma
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI).

Venture&Growth
Nalu Medical
Nalu Medical is a US medical device company that commercializes alternative proprietary neuromodulation systems. These systems treat chronic neuropathic pain in the back, legs, and other peripheral parts of the body, affecting 1.5 million patients. Nalu’s miniaturized implantable pulse generator
